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S U M M A R Y
Objectives: Increasing antimicrobial resistance is related to the selective pressure exerted by antibiotic
usage. This study evaluated the impact of the increased use of piperacillin/tazobactam (TZP) on the
selection of antibiotic resistance.
Methods: From 1999 to 2010, Escherichia coli and Klebsiella pneumoniae invasive isolates obtained from
hospitalized Korean children were analyzed in antibiotic susceptibility tests and subjected to
characterization of the b-lactamase types. Antibiotic consumption data were also analyzed.
Results: Between January 1999 and December 2010, 409 invasive isolates of E. coli (n = 170) and K.
pneumoniae (n = 239) were obtained. A rebound of extended-spectrum b-lactamase (ESBL) prevalence
with an increase in total antibiotics was noted. Non-susceptibility to TZP was determined in 7.6% of E. coli
isolates and 20.9% of K. pneumoniae isolates. Despite the increase in TZP usage, the overall prevalence of
TZP resistance did not signiﬁcantly increase over time, especially in E. coli. The mechanisms for TZP
resistance included the presence of AmpC producers, possible TEM-1 hyperproducers, and multiple b-
lactamases in individual organisms of a given isolate.
Conclusions: Replacement of only the antibiotic class appears to be insufﬁcient to control antibiotic
resistance, and continued efforts to decrease overall antibiotic pressure are needed, especially in highly
endemic situations.
 2013 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
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Extended-spectrum b-lactamase (ESBL)-producing Escherichia
coli and Klebsiella pneumoniae were ﬁrst described in the 1980s, but
are now recognized worldwide.1 It is well-established that
increases in antimicrobial resistance, including to b-lactams,
can be ascribed to the selective pressure exerted by antibiotic
usage, with the withdrawal of such pressure frequently used as an
effective means of resistance reversal.2,3
To control ESBL prevalence in the Seoul National University
Children’s Hospital, a policy restricting the use of extended-
spectrum cephalosporins (ESCs), replacing them with b-lactam/b-
lactamase inhibitor combinations such as piperacillin/tazobactam
(TZP) and ampicillin/sulbactam, has been instituted since 2002.4* Corresponding author. Tel.: +82 2 2072 3633; fax: +82 2 745 4703.
E-mail addresses: hoanlee@snu.ac.kr, hoanjlee@hanmail.net (H.J. Lee).
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http://dx.doi.org/10.1016/j.ijid.2013.01.030During a study carried out at our hospital from 1999 to 2005, the
overall ESBL prevalence decreased, with no increase in TZP
resistance determined among E. coli or K. pneumoniae isolates,
despite a signiﬁcant increase in the use of TZP.4
It has been reported that the clinical use of b-lactam/b-
lactamase inhibitor combinations results in the selection of point
mutants in TEM penicillinases resistant to inhibitors, referred to as
inhibitor-resistant TEMs (IRTs).5 These enzymes are generally
susceptible to cephalosporins.6 However, in the mid-1990s,
complex mutant TEMs (CMTs) that combine ESBL and IRT
mutations began to emerge among the TEM b-lactamases.7,8
Moreover, the detection in ESBL assays of strains producing CMT-
type b-lactamases may be difﬁcult because of their high-level
resistance to clavulanate. Another consequence of the increased
use of b-lactam/b-lactamase inhibitor combinations is the
emergence and spread of plasmids encoding AmpC b-lactamases.9
However, a signiﬁcant increasing trend in plasmid-mediated
AmpC producers or in producers of any other speciﬁc type ofses. Published by Elsevier Ltd. All rights reserved.
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TZP throughout the above-mentioned study period.4
In this study, the impact of the increased use of TZP on the
selection of antibiotic resistance, focusing on b-lactamase
producers among invasive E. coli and K. pneumoniae isolates
obtained from hospitalized Korean children, was evaluated,
following an extended study carried out from 1999 through
2010. Antibiotic consumption and the prevalence of antibiotic
resistance including ESBLs and TZP resistance were compared
during four periods: 1999–2001 (period 1; pre-intervention),
2002–2003 (period 2; transition period), 2004–2006 (period 3;
immediate post-intervention), and 2007–2010 (period 4; late post-
intervention).
2. Materials and methods
2.1. Study setting and bacterial isolates
Our institute is a 300-bed, university-afﬁliated, tertiary hospital
located in Seoul, Korea. E. coli and K. pneumoniae isolates from
normally sterile body ﬂuids were collected between January 1999
and December 2010 and kept at 70 8C. Species were identiﬁed
using VITEK-GNI cards (bioMe´rieux, Hazelwood, USA).
2.2. Susceptibility to b-lactams
The antibiotic susceptibility of each isolate was determined by
the disk diffusion method, as described by the Clinical and
Laboratory Standards Institute (CLSI).10 Minimum inhibitory
concentrations (MICs) were calculated using the E-test (AB Biodisk,
Solna, Sweden). Isolates with intermediate resistance or resistance
were deﬁned as non-susceptible.
2.3. Detection of ESBL- and AmpC-type b-lactamase producers
When suspected based on CLSI screening criteria, ESBL
production was conﬁrmed in a phenotypic CLSI conﬁrmatory
test.10 The production of AmpC-type b-lactamase was phenotypi-
cally suspected for isolates with reduced susceptibility to ESCs and
a negative clavulanic acid synergy test, and for those with a
decreased susceptibility to cefotetan or TZP. All of these strains
were further tested using boronic acid disks to screen for the
presence of AmpC b-lactamase.4
2.4. Identiﬁcation of ESBL types
For isolates obtained between 1999 and 2005, ESBL or AmpC b-
lactamase (both are designated as ESBLs from here on, unless
otherwise speciﬁed) types were identiﬁed by analytical isoelectric
focusing (with or without clavulanic acid and/or cloxacillin
inhibition) and/or sequencing of the respective b-lactamase genes,
as described previously.4,11 Only those TZP-resistant isolates
obtained since 2006 were subjected to PCR and sequencing of
the speciﬁed genes, i.e., TEM, SHV, CTX-M, OXA, DHA, and CMY,Table 1
Antibiotic usage during the study period
Year Antibiotic use (days/1000 patient-days/year)
Amp/sul TZP Cepha
1999–2001 69.5 1.3 20.9 
2002–2003 74.0 31.6 23.8 
2004–2006 64.4 54.4 36.2 
2007–2010 61.1 71.8 32.1 
p-Value for trenda 0.329 <0.001 0.062
Amp/sul, ampicillin/sulbactam; TZP, piperacillin/tazobactam; ESCs, extended-spectrum
a The p-value for trend was evaluated by linear-by-linear association.carried out in order to characterize the corresponding b-lactamase
genes.12–14
2.5. Antibiotic policy and antimicrobial consumption data
Beginning in 2002, to reduce the prevalence of ESBL producers,
the use of ESCs at our hospital was discouraged, and prescriptions
of b-lactam/b-lactamase inhibitor combinations were encouraged
instead. The annual amount of each class of antibiotic used in the
hospital was determined from the computerized hospital pharma-
cy database. Antibiotic consumption is expressed as days on the
antibiotic per 1000 patient admission days per year (AD).4,15
Although the antibiotic dosage and administration methods were
not thoroughly reviewed for individual cases, treatment guidelines
in the Pediatric Dosage Handbook were usually followed.16 In the
case of severe sepsis or febrile illness in neutropenic patients, the
maximum recommended dosage of antibiotic was used.
3. Results
3.1. Bacterial isolates
During the 12-year study period, between January 1999 and
December 2010, 409 isolates of E. coli (n = 170) and K. pneumoniae
(n = 239) grown from normally sterile body ﬂuids, including blood,
ascites, cerebrospinal ﬂuid, and closed pus, were identiﬁed based
on the records of the microbiology laboratory database.
3.2. Changes in antibiotic consumption
Following the introduction of TZP at our institute in 2001, the
use of TZP gradually increased, from 1.3 AD during period 1 to 71.8
AD during period 4 (Table 1). ESC use showed a statistically
signiﬁcant decreasing trend throughout the study period, although
a slight increase was observed during the last two periods, from
94.2 AD during period 3 to 102.2 AD during period 4. The patterns
of carbapenem usage and total amounts of antibiotics were similar,
with an overall nadir during period 3 and then an increasing trend.
By contrast, the total consumption of ampicillin/sulbactam and
cephamycins remained unchanged.
3.3. ESBL and AmpC b-lactamase detection
Among the 409 isolates, 18.8% (32 of 170) of E. coli isolates and
38.5% (92 of 239) of K. pneumoniae isolates were determined to be
ESBL or AmpC enzyme producers (Table 2). Among the E. coli
isolates, ESBL prevalence decreased gradually over the ﬁrst three
study periods, from 23.4% (11/47) during period 1 to 17.4% (4/23)
during period 2 and 9.3% (5/54) during period 3. However, during
period 4, the percentage of ESBL producers among E. coli
rebounded, reaching 24.2% (8/33). Among K. pneumoniae isolates,
the prevalence of ESBL producers showed a trend similar to that of
E. coli; thus, the ESBL prevalence decreased from 56.8% (25/44;
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 cephalosporins.
Table 2
Frequency of extended-spectrum b-lactamase (ESBL) producers and piperacillin/tazobactam (TZP) resistance among isolates of Escherichia coli and Klebsiella pneumoniae
between 1999 and 2010













1999–2001 2/47 (4.3)b 11/47 (23.4) 0/47 (0) 11/44 (25.0) 25/44 (56.8) 3/44 (6.8)
2002–2003 2/23 (8.7) 4/23 (17.4) 2/23 (8.7) 9/44 (20.5) 19/44 (43.2) 4/44 (9.1)
2004–2006 4/54 (7.4) 5/54 (9.3) 1/54 (1.9) 10/68 (14.7) 18/68 (26.5) 8/68 (11.8)
2007–2010 2/33 (6.1) 8/33 (24.2) 0/33 (0) 14/52 (26.9) 22/52 (42.3) 1/52 (1.9)
Total 13/170 (7.6) 32/170 (18.8) 3/170 (1.8) 50/239 (20.9) 92/239 (38.5) 20/239 (8.4)
p-Value for trendc 0.696 0.577 0.839 0.990 0.054 0.493
a ESBL and AmpC b-lactamase are jointly designated as ESBLs unless otherwise speciﬁed.
b The percentage of TZP-resistant strains among the total strains isolated in each time period.
c The p-value for trend was evaluated by linear-by-linear association.
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decreasing, albeit non-signiﬁcant, trend (Table 2).
3.4. TZP-resistant E. coli and K. pneumoniae
Non-susceptibility to TZP was determined in 13 (7.6%) E. coli
isolates and 50 (20.9%) K. pneumoniae isolates. Among the E. coli
isolates, TZP resistance was stationary over the course of the study:
4.3%, 8.7%, 7.4%, and 6.1% for periods 1 through 4, respectively (p
for trend = 0.696). Between 2006 and 2008, however, TZP-resistant
E. coli increased 20.0% (6/30), whereas AmpC producers were not
detected (Figure 1). Among K. pneumoniae, a drop in TZP resistance
from 25.0% to 20.5% and then to 14.7% occurred during periods 1, 2,
and 3, respectively, while during period 4, TZP-resistant K.
pneumoniae increased up to 26.9%.
3.5. Characterization of TZP resistance
Among the 63 TZP-resistant isolates, 13 isolates of E. coli and 40
isolates of K. pneumoniae were available for further microbiological
study, including b-lactamase characterization. The results of
antimicrobial susceptibility testing, reported as non-susceptible,
were as follows: 82.0% (41/50) for cefotaxime, 74.5% (38/51) for
ceftazidime, 26.0% (13/50) for cefepime, 54.7% (29/53) for cefoxitin
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Figure 1. Changes in antibiotic use, extended-spectrum b-lactamase (ESBL)
prevalence, and piperacillin/tazobactam resistance over 12 consecutive years
(1999–2010). The bar graph represents antibiotic usage, presented as days on
antibiotics per 1000 patient-days each year. The solid line shows the prevalence of
ESBL and the dotted line shows the prevalence of ESBL among Escherichia coli (open
triangles) and Klebsiella pneumoniae (open squares).Among the 13 TZP-resistant E. coli isolates, only three were
positive in a boronic acid test and were conﬁrmed to produce
AmpC enzymes, i.e., CMY-1 (n = 1), CMY-2 (n = 1), and DHA-1
(n = 2) (Table 3). Two isolates simultaneously produced both CMY-
2 and DHA-1, whereas the remaining 10 isolates did not produce
AmpC enzymes. All of the TZP-resistant E. coli produced TEM
enzymes (TEM-1-like, 10 isolates; TEM-52, two isolates; and TEM-
106, two isolates), of which none were IRTs or CMTs. None of the
isolates produced ESBLs of the CTX-M family, whereas two SHV-
type ESBLs, SHV-2a and SHV-11, were detected.
Among the 40 TZP-resistant K. pneumoniae isolates, 15 were
positive by boronic acid testing and produced the AmpC enzymes,
CMY-1 (n = 4) and DHA-1 (n = 11) (Table 4). One of the K.
pneumoniae isolates producing DHA-1 was negative by boronic
acid testing. TEM enzymes were produced by 18 isolates: TEM-1-
like enzymes were detected in 16 isolates, TEM-52-like in two, and
TEM-106-like in one. None of these enzymes were IRT- or CMT-
type b-lactamases. CTX-M-type ESBLs were present in only four
isolates: CTX-M-12 (n = 3) and CTX-M-14 (n = 1). Among the TZP-
resistant K. pneumoniae isolates, SHV-type enzymes were detected
in 32: SHV-12-like (n = 13), SHV-2a (n = 8), SHV-1-like (n = 5),
SHV-11-like (n = 5), and SHV-133 (n = 1).
Thus, overall, 10 out of 13 E. coli isolates and 24 of 40 K.
pneumoniae isolates resistant to TZP did not produce either AmpC
enzyme or IRTs/CMTs.
4. Discussion
Among Enterobacteriaceae, the most prevalent mechanism of
acquired resistance to b-lactams is the production of b-
lactamases. The penicillinases TEM-1 and SHV-1 hydrolyze only
penicillins and narrow-spectrum cephalosporins, whereas these
enzymes are inhibited by ESCs and b-lactamase inhibitors, such as
clavulanate and tazobactam. However, certain amino acid sub-
stitutions confer hydrolytic activity against ESCs under pressure of
these antibiotics, and these ESBLs are usually susceptible to b-
lactamase inhibitors.17 Meanwhile, strains producing IRTs, CMTs,
or AmpC b-lactamases were found to be generally resistant to
inhibitor combinations, and the presence of these enzymes was
associated with the increased use of b-lactam/b-lactamase
inhibitor combinations.5,6,9 To decrease the ESBL prevalence at
our institute, a change in antibiotic policy was initiated in 2002;
thus, TZP rather than ESCs was encouraged for the treatment of
Gram-negative bacterial infections, including in febrile neutrope-
nic cancer patients. In a previous study carried out from 1999
through 2005, the overall prevalence at our hospital of ESBL
producers among invasive isolates of E. coli and K. pneumoniae
signiﬁcantly decreased, from 39.8% (41/103) to 22.8% (18/79) (p for
trend = 0.018).4 However, beginning in 2005, when the total
amount of antibiotic use and the ESBL prevalence had reached a
Table 3
Characterization of piperacillin/tazobactam-resistant Escherichia coli
Serial No. Year of isolation TZP MIC by E-test (mg/ml) ESBL or AmpC enzyme characteristics ESBL conﬁrmatory test Boronic acid test
1 2004 24 TEM-1 Negative Negative
2 2006 256 TEM-1 Negative Negative
3 2006 256 TEM-1 Negative Negative
4 2007 256 TEM-1, OXA Negative Negative
5 1999 32 TEM-1, TEM-52 Positive Negative
6 2001 64 TEM-1, TEM-52 Positive Negative
7 2007 >256 TEM-1 Positive Negative
8 2007 256 TEM-106, OXA Positive Negative
9 2008 256 TEM-106 Positive Negative
10 2009 256 TEM-1, SHV-11 Positive Negative
11 2002 32 TEM-104, CMY-1 Negative Positive
12 2004 256 TEM-1, CMY-2, DHA-1 Negative Positive
13 2003 256 TEM-1, SHV-2a, DHA-1 Positive Positive
TZP, piperacillin/tazobactam; MIC, minimum inhibitory concentration; ESBL, extended-spectrum b-lactamase.
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pneumoniae were observed, along with an increase in the amount
of total antibiotics, including not only TZP but also ESCs and
carbapenems. Therefore, replacement of only the antibiotic class
appears to be insufﬁcient to control ESBL prevalence. Instead,
broader efforts to decrease overall antibiotic pressure are needed
in order to reduce resistant bacteria in highly endemic situations.
In this extended study, a statistically signiﬁcant change in TZP
resistance among E. coli and K. pneumoniae was not observed,
despite a sharp increase in the use of this antibiotic combination.Table 4
Characterization of piperacillin/tazobactam-resistant Klebsiella pneumoniae
Serial No. Year of isolation TZP MIC by E-test (mg/ml) ESBL or Amp
1 1999 96 TEM-1, SHV-
2 2000 256 TEM-1, SHV-
3 2004 256 SHV-2a 
4 2006 256 TEM-1, SHV-
5 2007 64 SHV-1 
6 2007 128 SHV-1 
7 2010 256 SHV-11 
8 2010 256 SHV-1 
9 1999 >128 TEM-1, SHV-
10 2000 256 TEM-1, SHV-
11 2001 256 TEM-52 
12 2001 256 SHV-2a 
13 2002 256 TEM-1, CTX-
14 2003 256 SHV-2a 
15 2003 256 TEM-1, SHV-
16 2003 128 TEM-1, SHV-
17 2004 256 SHV-12 
18 2005 16 SHV-12 
19 2007 256 TEM-1, SHV-
20 2007 256 CTX-M-12, O
21 2009 256 TEM-1, SHV-
22 2009 256 SHV-2a 
23 2010 256 None 
24 2000 >128 SHV-2a 
25 2000 >128 TEM-1, SHV-
26 1999 64 TEM-1, DHA-
27 2002 48 SHV-12, CMY
28 2002 256 TEM-1, TEM-
29 2006 256 SHV-11, DHA
30 2006 256 SHV-11, DHA
31 2006 128 SHV-1, DHA-
32 2003 256 SHV-12, CMY
33 2006 256 TEM-1, SHV-
34 2007 256 SHV-133, OX
35 2001 256 SHV-12, CMY
36 2002 128 TEM-1, CMY-
37 2004 256 TEM-1, DHA-
38 2005 256 SHV-12, DHA
39 2007 256 SHV-12, CTX
40 2008 24 TEM-106, SH
TZP, piperacillin/tazobactam; MIC, minimum inhibitory concentration; ESBL, extendedThe reasons are currently unknown, but a similar phenomenon
was observed by Patterson et al. and described in our previous
study.4,15 However, TZP pressure exerted a greater inﬂuence on K.
pneumoniae than on E. coli. Thus, TZP resistance among K.
pneumoniae reached a nadir at 14.7% during period 3 but nearly
doubled, to 26.9%, during period 4, whereas there was no
signiﬁcant increase in TZP resistance among E. coli between
periods 3 and 4. In our previous study, the revised antibiotic policy
was also found to have had a greater impact on K. pneumoniae than
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V-11, OXA, DHA-1 Positive Positive
-spectrum b-lactamase.
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in antibiotic pressure, with K. pneumoniae being more vulnerable
to the acquisition and loss of resistance genes.
Resistance to b-lactamase inhibitor combinations including
TZP in E. coli and K. pneumoniae can emerge as a consequence of
various mechanisms. Characteristically, AmpC b-lactamases pro-
vide resistance to cephamycins as well as ESCs, whereas these
enzymes are resistant to inhibition by clavulanic acid.18 Since K.
pneumoniae does not possess chromosomal ampC, the AmpC
enzymes such as DHA-1 and CMY-1 detected in K. pneumoniae
isolates were plasmid-mediated ampC genes. In E. coli, although
the expression of chromosomal ampC is not inducible, in some
strains of the bacterium this gene is constitutively overexpressed.
The hyperproduction of constitutive chromosomal b-lactamases
such as AmpC in E. coli and SHV-1 in K. pneumoniae can reduce the
activity of b-lactam/b-lactamase inhibitor combinations.19 How-
ever, in this study it was not determined whether the AmpC
enzymes expressed among E. coli were plasmid-mediated or
chromosomally mediated. Since plasmid-mediated genes can
spread in the hospital setting, the distinction between plasmid
and chromosomal enzymes is important in the control of hospital
infections.20 In this study, AmpC enzymes were detected in 23.1%
(3/13) of TZP-resistant E. coli isolates and 40% (16/40) of TZP-
resistant K. pneumoniae isolates, with DHA-1 being the most
frequently identiﬁed enzyme. However, an increasing trend in the
prevalence of AmpC producers among E. coli and K. pneumoniae has
yet to be detected.
For the TZP-resistant strains lacking AmpC enzymes, the
inoculum effect, b-lactamase hyperproduction, and modiﬁcations
in the outer membrane protein proﬁle have been suggested to
inﬂuence the susceptibility of E. coli and K. pneumoniae to b-
lactamase inhibitor combinations.21 The hyperproduction of TEM-
1 b-lactamase due to the presence of either strong promoters or
multiple blaTEM-1 copies may result in a loss of susceptibility to b-
lactam/b-lactamase inhibitor combinations.22,23 The hyperpro-
duction of SHV-1 or its ESBL variants has also been described.24 In
our study, most of the TZP-resistant E. coli isolates carried the TEM-
1 enzyme, although we did not evaluate copy numbers. Future
work should focus on the investigation of TEM-1 hyperproducers
in E. coli and SHV-1 and its variants in K. pneumoniae as a cause of
TZP resistance. The observed TZP resistance may have been due to
the expression of multiple b-lactamases within a single organism,
which could lead to variable resistance patterns and might account
for the decreased susceptibility to the b-lactamase inhibitors
observed in this study.19
Among the TZP-resistant strains reported herein, neither IRT
nor CMT enzymes were detected; nonetheless, continuous
monitoring to guard against the emergence of these types of b-
lactamase is needed. Most IRT- and CMT-producing strains are
susceptible in vitro to TZP because of the lower activity of their
inhibitors under these conditions.6 Here, the presence of IRT or
CMT enzymes was evaluated only as an attempt to explain the
occurrence of the TZP-resistant isolates, such that the true impact
of the increased use of TZP on the emergence of IRT or CMT could
not be evaluated thoroughly. In particular, TZP is not bactericidal
against most IRT-producing strains of E. coli, especially in the case
of high bacterial inoculums. Thus, for the treatment of severe
infections caused by IRT-producing organisms, regimens based on
relatively high doses might be required to prevent a possible loss of
the bactericidal effect.25
There are some limitations in this study besides those
mentioned above. Speciﬁcally, for the characterization of TZP-
resistant isolates, only qualitative PCR and sequencing analysis of
b-lactamase genes were performed, whereas possible defects in
outer membrane proteins such as OmpF and/or OmpC porins were
not evaluated. Given that a lack of porins does not signiﬁcantlyaffect susceptibility to b-lactams in the absence of a b-
lactamase,19 further studies of outer membrane permeability are
needed to clarify the resistance mechanisms. In addition, the
methodology of PCR and sequencing used in the detection of
candidate b-lactamase genes was limited; further in-depth studies
will no doubt shed further light on the mechanisms of TZP
resistance.
In conclusion, replacement of only the antibiotic class was
insufﬁcient to control resistant bacteria in this highly endemic
situation. In this extended study, rebounds in the prevalence of
ESBL among invasive isolates of E. coli and K. pneumoniae were
observed, along with an increase in total antibiotic usage, including
extended-spectrum b-lactams and TZP. The mechanisms for TZP
resistance in this study might include the presence of AmpC
producers, multiple b-lactamases in individual organisms of a
given isolate, and possible TEM-1 hyperproducers. Despite the
increase in TZP usage, the overall prevalence of isolates resistant to
TZP did not signiﬁcantly increase over time especially in the case of
E. coli, which suggests a relatively higher threshold of resistance
acquisition. Continued efforts to decrease overall antibiotic
pressure are needed in order to control resistant bacteria in
highly endemic situations.
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